On Tuesday, Seelos Therapeutics Inc (NASDAQ: SEEL) opened lower -9.97% from the last session, before settling in for the closing price of $0.29. Price fluctuations for SEEL have ranged from $0.22 to $291.60 over the past 52 weeks.
Here's Your FREE Report on the #1 Small-Cap Uranium Stock of '24.
Small-cap Uranium stocks are booming in 2024! The company we're about to show you is the ONLY small-cap stock in the space that benefits from ALL aspects of the global Uranium industry with none of the risks of running a mine. Smart investors will not be hesitating on this one!
Get the FREE Report with all the details here.
Sponsored
Over the past five-year period, the drop rate of yearbook sales for the company of the Healthcare sector was -20.00%. With a float of $6.73 million, this company’s outstanding shares have now reached $6.98 million.
Considering the fact that the conglomerate employs 16 people, you should pay attention to its efficiency factor. In terms of profitability, gross margin is 97.07%, operating margin of -1480.04%, and the pretax margin is 203.13%.
Seelos Therapeutics Inc (SEEL) Insider Activity
A key investor’s attitude towards the stock of the Biotechnology industry is another important factor to consider. The insider ownership of Seelos Therapeutics Inc is 3.48%, while institutional ownership is 3.06%. The most recent insider transaction that took place on Nov 30 ’23, was worth 100,222. In this transaction Chief Financial Officer of this company bought 83,000 shares at a rate of $1.21, taking the stock ownership to the 86,450 shares. Before that another transaction happened on Dec 01 ’23, when Company’s insider bought 75,757 for $1.32, making the entire transaction worth $99,999. This insider now owns 185,142 shares in total.
Seelos Therapeutics Inc (SEEL) Earnings and Forecasts
If we go through the results of last quarter, which was made public on 12/31/2023, the company posted -28.8 earnings per share (EPS) for the quarter, coming under the agreed prediction (set at -26.4) by -2.4. Wall Street market experts anticipate that the next fiscal year will bring earnings of 0 per share during the current fiscal year.
Seelos Therapeutics Inc (NASDAQ: SEEL) Trading Performance Indicators
Check out the current performance indicators for Seelos Therapeutics Inc (SEEL). In the past quarter, the stock posted a quick ratio of 0.08. In addition, a publicly-traded company’s price to sales ratio for the trailing twelve months stands at 0.91.
For the trailing twelve months, Company’s Diluted EPS (Earnings per Share) is 11.04
Technical Analysis of Seelos Therapeutics Inc (SEEL)
Compared to the last year’s volume of 0.77 million, its volume of 0.34 million showed lagged in the last five days. As of the previous 9 days, the stock’s Stochastic %D was 22.89%. Additionally, its Average True Range was 0.06.
During the past 100 days, Seelos Therapeutics Inc’s (SEEL) raw stochastic average was set at 0.99%, which indicates a significant decrease from 17.14% during the past two weeks. Based on volatility metrics of the stock, it showed a historical volatility of 233.94% in the past 14 days, which was higher than the 139.51% volatility it showed in the past 100 days.
At the time of writing, stock’s 50-day Moving Average is $0.4349, while its 200-day Moving Average is $5.9358. Nevertheless, the first resistance level for the watch stands at $0.3011 in the near term. At $0.3394, the stock is likely to face the second major resistance level. The third major resistance level sits at $0.3641. If the price goes on to break the first support level at $0.2381, it is likely to go to the next support level at $0.2134. Should the price break the second support level, the third support level stands at $0.1751.
Seelos Therapeutics Inc (NASDAQ: SEEL) Key Stats
There are currently 2,173K shares outstanding in the company with a market cap of 1.83 million. Presently, the company’s annual sales total 2,200 K according to its annual income of -37,880 K. Last quarter, the company’s sales amounted to 380 K and its income totaled 1,710 K.
